None listed
Conditions
Interventions
None listed
Sponsors
Chonnam National University Hwasun Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Adults over the age of 19 with smartphone 2.Patients taking any of the following medications (oral anticancer or antiarrhythmic drugs; Abemaciclib, Alectinib, Capecitabine, Ceritinib, Crizotinib, Ibrutinib, Lapatinib, Lazertinib, Lenvatinib, Lorlatinib, Osimertinib, Ponatinib, Ribociclib, Sorafenib, Sunitinib, Vandetanib, Vemurafenib , Amiodarone, Dronedarone, Flecainide, Pilsicainide, Propafenone, Sotalol ) and have had an electrocardiogram within 1 year of study enrollment 3.Those who agree to research and can understand and carry out training and instructions
Exclusion criteria
Exclusion criteria: Individuals with physical disabilities preventing the use of the portable electrocardiogram device, HATIV® Individuals with intracardiac devices such as pacemakers, ICD, CRT, VAD Subjects who are unable to read the informed consent form (illiterate, foreigners, etc.) Patients deemed inappropriate for participation in the clinical study based on the judgment of the researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic rates of clinically significant arrhythmia events over three months | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient-reported outcomes | — |
Countries
Korea, Republic of
Contacts
Public ContactKi hong Lee
Chonnam National University Hospital
Outcome results
None listed